Brief: Eloxx Pharmaceuticals Adds Additional Treatment Arm To Ongoing Phase 2 Clinical Studies For Cystic Fibrosis
29/04/2021 23:09
April 29 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS ADDS ADDITIONAL TREATMENT ARM TO
ONGOING
PHASE 2 CLINICAL STUDIES FOR CYSTIC FIBROSIS
* ELOXX PHARMACEUTICALS INC - REAFFIRMED DATA READOUT FOR
FIRST
FOUR TREATMENT ARMS ON TRACK FOR SECOND HALF OF 2021
* ELOXX PHARMACEUTICALS INC - FIFTH TREATMENT ARM TO
EVALUATE
SAFETY OF ELX-02 IN COMBINATION WITH KALYDECO (IVACAFTOR)
Source text for Eikon: ID:nGNX1QQrKc
Further company coverage: ELOX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome